UPDATE: Bank Of America Reiterates On Abbott Laboratories Following Detailed Analysis

In a report published Thursday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on Abbott Laboratories ABT, and raised the price target from $39.00 to $46.00. In the report, Bank of America noted, “We expect ABT to continue to grow earnings in the double-digit range on an organic basis over the next several years. Although ABT has gained additional attractive exposure to emerging markets through recent M&A activities, we need more conviction around the size and duration of these opportunities and the uncertainties around the healthcare industry in general before we can become more positive on the stock.” Abbott Laboratories closed on Wednesday at $41.27.